B系急性淋巴细胞白血病中CD20表达及其对预后影响  

CD20 Expression in Adult Patients with B-lineage Acute Lymphoblastic Leukemia and Its Prognostic Significance

作　　者：周进[1] 王婧[1] 刘辉[1] 郑慧菲 马玲[1] 王攀峰[1] 颜霜[1] 傅琤琤[1] 

机构地区：[1]苏州大学附属第一人民医院血液科

出　　处：《中国实验血液学杂志》2015年第3期619-622,共4页Journal of Experimental Hematology

摘　　要：目的:探讨白细胞分化抗原CD20在B系急性淋巴细胞白血病(B-ALL)中的临床特征与及其对治疗转归影响。方法:回顾性分析2009年7月至2012年7月在我院血液科诊断和治疗的B-ALL患者126例临床特征及治疗转归,比较CD20阳性患者及CD20阴性患者第1疗程诱导治疗完全缓解率、复发率及2年生存率、2年无事件生存率。结果:126例B-ALL患者中CD20阳性患者31例(24.4%),CD20阴性患者95例(75.6%);在性别及年龄分布中,CD20阳性组和CD20阴性组间的差异无统计学意义。CD20阳性与阴性患者经第1疗程诱导治疗后获完全缓解率分别为88.2%(15/17),90.5%(57/63)(P>0.05),复发率分别为53.3%(8/15),38%(19/50);2年总生存率分别为52.1%,92.3%;2年无事件生存率分别为33.7%,70.8%。结论:CD20在B-ALL CD20表达与临床特点方面无明显相关性,但其表达可能提示预后不良。Objective： To explore the relationship between the expression of CD20 antigen and clinical characteristics in adult patients with B-acute lymphoblastic leukemia（B-ALL）. Methods：The CD20 expression of 126 acute lympho- blastic leukemia patients in our hospital from July 2009 to July 2012 were determined by flow cytometry. The characteristics, examination results and outcome were analyzed retrospectively. The complete remission rate （CR rate）, relape rate, 2 - year survival rate and 2 - year event - free survival （ EFS ） of patients with CD20 positive and negative after the first cycle of chemstherapy were compared. Results ：Positive rate of CD20 antigen expression in 126 patients was 24.4% （31 cases）, negative rate of CD20 antigen expression in 126 patients was 75.6% （95 cases）. No significant relationship was found between CD20 antigen expression and sex, age, peripheral blood leucocytes count and chromosomal changes. The relapse rate, 2-year survival rate（OS） and 2-year event-free survival （EFS） of adult patients with B-ALL in CD20 positive and negative groups were 53.3% and 38.0%, 52.1% and 92.3%, 33.7% and 70.8% respectively. Conclusion： Expression of CD20 in adult patients with B-ALL did not related with clinical features, but related with poor prognosis.

关 键 词：B系急性淋巴细胞白血病 CD20 预后 

分 类 号：R733.71[医药卫生—肿瘤]